美股异动｜远程医疗公司LifeMD涨超5%，与诺和诺德就售卖Ozempic达成合作

Core Viewpoint - LifeMD has partnered with Novo Nordisk to offer the diabetes medication Ozempic to eligible U.S. patients at a monthly price of $499, leading to a stock price increase of over 5% to $6.77 [1] Company Summary - LifeMD's stock rose more than 5%, reaching $6.77 following the announcement of its collaboration with Novo Nordisk [1] - The partnership aims to provide Ozempic, a diabetes medication, to qualifying patients in the United States [1] - The monthly cost for patients to access Ozempic through this program is set at $499 [1]